DB18132InvestigationalProtein Based Therapies
PMC-403 is a novel Tie2-activating antibody being investigated for the treatment of systemic capillary leak syndrome.
- Mechanism
- Curator reviewed
Pharmacologically active on Angiopoietin-1 receptor
- Also known as
- a fully human monoclonal antibody that binds and activates the Tie2 receptor
- Code names
- PMC 403
Resolves to
Targets
What you can answer from here — as of July 08, 2026
Which drugs share a target with PMC-403, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account